Search
Prolgolimab
go.drugbank.com/drugs/DB16740InvestigationalCategories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitorsINKP-102
go.drugbank.com/drugs/DB05326ExperimentalINKP-102 is the next generation sodium phosphate tablet designed to aid bowl preparation before colonoscopy.
ISIS 14803
go.drugbank.com/drugs/DB05803InvestigationalISIS 14803 is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits protein expression in cell cul...
Disoxaril
go.drugbank.com/drugs/DB08726ExperimentalThese are aromatic compounds containing an ether group substituted with a benzene ring.
Synonyms: 3-METHYL-5-(7-(P-2-OXAZOLIN-2-YLPHENOXY)HEPTYL)ISOXAZOLEMidomafetamine
go.drugbank.com/drugs/DB01454IllicitInvestigationalAn N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesDCLL-9718S
go.drugbank.com/drugs/DB17392InvestigationalDCLL9718S is an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1).
Tetrahydropalmatine
go.drugbank.com/drugs/DB12093InvestigationalTetrahydropalmatine is under investigation in clinical trial NCT02118610 (Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity).
Categories: Dopamine D2 Receptor Antagonists, Cytochrome P-450 SubstratesPGX-100
go.drugbank.com/drugs/DB06114InvestigationalPGX-100 is an intravenous dosage form of modified heparin.
Meglutol
go.drugbank.com/drugs/DB04377ExperimentalAn antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids.
Mupadolimab
go.drugbank.com/drugs/DB16488InvestigationalCPI-006 was investigated in clinical trials NCT03454451, NCT04464395, and NCT04734873 to evaluate its safety and efficacy. NCT03454451 focused on advanced cancers (e.g., non-small cell lung cancer, renal cell cancer, colorectal cancer). ...